Ipamorelin is a pentapeptide growth hormone secretagogue that binds the ghrelin receptor (GHSR) with high selectivity for GH release. It is considered the most selective GHRP due to its minimal effects on cortisol, prolactin, and appetite compared to other compounds in its class.
Structure and Mechanism
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide that was developed through systematic structure-activity optimization of earlier GHRPs. It binds to the growth hormone secretagogue receptor type 1a (GHSR-1a, the ghrelin receptor) on anterior pituitary somatotroph cells. Upon receptor activation, intracellular calcium increases through phospholipase C signaling, stimulating GH vesicle exocytosis. Unlike GHRP-6 and hexarelin, ipamorelin does not appreciably activate the ACTH-cortisol axis at GH-releasing doses, nor does it significantly stimulate prolactin secretion.
This selectivity profile arises from ipamorelin’s specific binding characteristics. While it activates GHSR-1a with sufficient potency to release GH, it appears to do so with a receptor interaction that does not engage the same downstream pathways responsible for cortisol and prolactin release seen with less selective GHRPs. The exact molecular basis for this selectivity remains an active area of investigation in receptor pharmacology research.
Research Findings
Published studies have characterized ipamorelin’s GH-releasing efficacy across multiple models. In preclinical research, ipamorelin produces dose-dependent GH release with a clear dose-response relationship. The GH response follows first-order kinetics with peak levels observed approximately 15–20 minutes after administration. Importantly, ipamorelin’s GH-releasing effect is subject to negative feedback — co-administration of somatostatin blocks the response, confirming that release occurs through physiological pituitary mechanisms rather than bypassing normal regulatory controls.
Studies comparing ipamorelin to GHRP-6 and GHRP-2 have demonstrated that while the absolute GH release may be somewhat lower, the specificity for GH over other pituitary hormones is superior. This makes ipamorelin the preferred tool compound when researchers need to study GH-mediated effects in isolation, without confounding changes in cortisol or prolactin that might influence experimental outcomes.
Combination Research Protocols
Ipamorelin is frequently studied in combination with GHRH analogs like CJC-1295 (modified GRF 1-29). Because ipamorelin and GHRH analogs act through different receptors (GHSR and GHRHR respectively), their combination produces synergistic GH release. This synergy allows lower doses of each compound to achieve greater GH responses than either alone at higher doses, a principle that guides many current preclinical research protocols examining GH axis physiology.
Frequently Asked Questions
Why is ipamorelin considered the most selective GHRP?
Ipamorelin releases GH without significantly increasing cortisol, ACTH, prolactin, or aldosterone at effective GH-releasing doses. Other GHRPs like GHRP-6 stimulate appetite (via ghrelin-like activity) and raise cortisol levels, while hexarelin can elevate prolactin. Ipamorelin’s clean pharmacological profile makes it the preferred research tool for studying isolated GH effects without these confounding hormonal changes.
What is the typical dose range used in research?
Preclinical research protocols typically use ipamorelin at 100–300 mcg per administration in rodent models, scaled by body weight. Dose-response studies examine ranges from 1 mcg/kg to 1000 mcg/kg to characterize the full activity curve. The effective dose varies by species, route of administration, and study objective. Refer to published literature for species-specific dosing guidance and use our dosage calculator for unit conversions.